Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

QINLOCK

RIPRETINIB

Standard Dose
50MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview QINLOCK is listed in Drugs@FDA under application 213973 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient RIPRETINIB Form and strength TABLET;ORAL - 50MG Sponsor DECIPHERA PHARMS Submission history Latest submission status date: 2025-05-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview QINLOCK is listed in Drugs@FDA under application 213973 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient RIPRETINIB Form and strength TABLET;ORAL - 50MG Sponsor DECIPHERA PHARMS Submission history Latest submission status date: 2025-05-06 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.